<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977960</url>
  </required_header>
  <id_info>
    <org_study_id>MINECRAFT</org_study_id>
    <nct_id>NCT04977960</nct_id>
  </id_info>
  <brief_title>Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19</brief_title>
  <acronym>MINECRAFT</acronym>
  <official_title>MINECRAFT Study: MINEralcorticoid Receptor Antagonism With CanRenone As eFfective Treatment in Moderate to Severe ARDS in COVID-19, a Phase 2 Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on&#xD;
      therapy on maximal medical treatment versus maximal medical treatment alone in treating&#xD;
      moderate-to-severe ARDS due to SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, 1:1 randomized parallel arms, Simon's two stage design, single centre.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-hospital death</measure>
    <time_frame>At the event (discharge or death)</time_frame>
    <description>patients discharged to a long-term care facility will be classified as &quot;discharged alive&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need of invasive mechanical ventilation throughout hospitalization</measure>
    <time_frame>at discharge or death</time_frame>
    <description>Researchers will record if mechanical ventilation has been required during hospitalization (YES) or not (NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization for alive patients</measure>
    <time_frame>From date of randomization until the date discharge or in-hospital death from any cause, whichever came first, assessed up to 48 months</time_frame>
    <description>from randomization to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug intolerance</measure>
    <time_frame>From the date of randomization until three days after the end of IMP administration (10 days after randomization)</time_frame>
    <description>measured as number of AR and SAR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypotensive events</measure>
    <time_frame>From the date of randomization until three days after the end of IMP administration (10 days after randomization)</time_frame>
    <description>defined as systolic blood pressure constantly &lt;90 mmHg and diastolic blood pressure constantly &lt;60 mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperkaliemias events</measure>
    <time_frame>From the date of randomization until three days after the end of IMP administration (10 days after randomization)</time_frame>
    <description>defined as [K+]hematic &gt;5.1 mEq/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of renal failures</measure>
    <time_frame>From the date of randomization until three days after the end of IMP administration (10 days after randomization)</time_frame>
    <description>defined as eGFR &lt;30 ml/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sequential Organ Failure Assessment (SOFA) score from randomization to 7 days after randomization</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>A score from 0 (better outcome) to 4 (worst outcome) for six different systems (respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems) will be assessed and recorded in CRF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory status</measure>
    <time_frame>at 48 hours and 168 hours (7th day) from randomization</time_frame>
    <description>CRP levels, IL-6, Ddimer and Ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory parameters</measure>
    <time_frame>at 48 hours and 168 hours (7th day) from randomization</time_frame>
    <description>Heart Rate, Blood Pressure (mmHg), PaO2/FiO2 (mmHg), alveolar-arterial gradient (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in features of pulmonary interstitial disease measured by chest X-Ray</measure>
    <time_frame>at 7 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in [K+]hematic, renin, AngII, Ang1-7, Ang1-9, aldosterone and structurally related steroids</measure>
    <time_frame>at randomization and at 48 and 168 hours (7th day) from randomization</time_frame>
    <description>[K+]hematic will be expressed as mEq/L Plasmatic Renin Activity will be expressed as µUI/mL Hematic Concentration of AngII, Ang1-7, Ang1-9, aldosterone and structurally related steroids will be expressed as ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between levels of [K+]hematic, renin, AngII, Ang1-7, Ang1-9, aldosterone and structurally related steroids, at basal level (randomization) and clinical outcomes (in-hospital death, need of invasive mechanical ventilation, SOFA score)</measure>
    <time_frame>at randomization and at 48 and 168 hours (7th day) from randomization</time_frame>
    <description>[K+]hematic will be expressed as mEq/L Plasmatic Renin Activity will be expressed as µUI/mL Hematic Concentration of AngII, Ang1-7, Ang1-9, aldosterone and structurally related steroids will be expressed as ng/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Reference group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to the Reference Group will receive the standard-of-care treatments, according to institutional procedures in force:&#xD;
Dexamethasone i.v. 6 mg die for consecutive 5 days&#xD;
Methylprednisolone i.v. 40 mg bid for consecutive 10 days&#xD;
Low-molecular-weight-heparin i.v. at standardized dose of 70 UI/kg twice&#xD;
Remdesivir i.v. 200 mg in bolus (1st day) then 100 mg die for 4 days; remdesivir will be used only in patients supported with low-flow nasal cannula oxygen or Venturi mask&#xD;
Antibiotic therapy:&#xD;
azithromycin: 500 mg/die per os for 5 days&#xD;
ceftriaxone: 2 g i.v. die for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized in the Experimental Group will receive canrenone as add-on therapy to standard-of-care treatments. Different starting doses of i.v. canrenone will be administrated in a single or double infusion per day, for 7 days, according to the serum concentration of potassium at randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Canrenoate</intervention_name>
    <description>potassium canrenoate for 7 days in addition to maximal medical treatment</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Canrenone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 80 y.o. Since over eighties are very fragile patients, a lot of confounding&#xD;
             unpredictable events may interfere with the trial analyses; thus, these patients will&#xD;
             be excluded from this exploratory proof-of-concept trial;&#xD;
&#xD;
          -  COVID-19 diagnosis through swab within 14 days from the beginning of symptoms&#xD;
&#xD;
          -  Hospitalization for moderate to severe ARDS (as determined by PaO2/FiO2 ≤300 mmHg at&#xD;
             admission)&#xD;
&#xD;
          -  Serum concentration of potassium ≤4.5 mEq/L&#xD;
&#xD;
          -  Consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Invasive mechanical ventilation&#xD;
&#xD;
          -  I.v. hydratation with Darrow's solution or half-strength Darrow's solution underway&#xD;
&#xD;
          -  Acute cardiovascular event (acute myocardial infarction, acute ischaemic stroke)&#xD;
&#xD;
          -  Current malignant disease&#xD;
&#xD;
          -  Creatinine &gt;1.8 mg/dL (for women) and &gt;2.0 mg/dL (for men) or glomerular filtration&#xD;
             rate &lt;50 mL/mm&#xD;
&#xD;
          -  Systolic blood pressure &lt;110 mmHg and/or diastolic blood pressure &lt;60 mmHg&#xD;
&#xD;
          -  Known or suspected hypersensitivity to canrenone&#xD;
&#xD;
          -  Hyponatremia&#xD;
&#xD;
          -  Anuria&#xD;
&#xD;
          -  Familial history of porphyria&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  known or suspected hypersensitivity to canrenone&#xD;
&#xD;
          -  Inclusion in any other pharmacological clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Vicenzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Vicenzi, MD</last_name>
    <phone>+390255033537</phone>
    <email>marco.vicenzi@policlinico.mi.it</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>potassium canrenoate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canrenone</mesh_term>
    <mesh_term>Canrenoic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

